322 related articles for article (PubMed ID: 27105109)
1. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.
Mahmoud F; Shields B; Makhoul I; Hutchins LF; Shalin SC; Tackett AJ
Cancer Biol Ther; 2016 Jun; 17(6):579-91. PubMed ID: 27105109
[TBL] [Abstract][Full Text] [Related]
2. Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy.
Terranova CJ; Tang M; Maitituoheti M; Raman AT; Ghosh AK; Schulz J; Amin SB; Orouji E; Tomczak K; Sarkar S; Oba J; Creasy C; Wu CJ; Khan S; Lazcano R; Wani K; Singh A; Barrodia P; Zhao D; Chen K; Haydu LE; Wang WL; Lazar AJ; Woodman SE; Bernatchez C; Rai K
Cell Rep; 2021 Jul; 36(3):109410. PubMed ID: 34289358
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
5. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
6. 3-deazaneplanocin A, a histone methyltransferase inhibitor, improved the chemoresistance induced under hypoxia in melanoma cells.
Hosokawa M; Tetsumoto S; Yasui M; Kono Y; Ogawara KI
Biochem Biophys Res Commun; 2023 Oct; 677():26-30. PubMed ID: 37542772
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
[TBL] [Abstract][Full Text] [Related]
9. Ezh2
Zimmerman SM; Nixon SJ; Chen PY; Raj L; Smith SR; Paolini RL; Lin PN; Souroullas GP
Oncogene; 2022 Nov; 41(46):4983-4993. PubMed ID: 36220978
[TBL] [Abstract][Full Text] [Related]
10. Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.
Anwar T; Gonzalez ME; Kleer CG
Am J Pathol; 2021 May; 191(5):774-783. PubMed ID: 33556366
[TBL] [Abstract][Full Text] [Related]
11. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
12. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML; Athar M; Ferguson JE; Varambally S
Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
[TBL] [Abstract][Full Text] [Related]
13. Role of EZH2 in bone marrow mesenchymal stem cells and immune-cancer interactions.
Liu Z; Jia Y; Guo Y; Wang H; Fu R
Crit Rev Oncol Hematol; 2022 Jan; 169():103547. PubMed ID: 34843930
[TBL] [Abstract][Full Text] [Related]
14. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P
Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929
[TBL] [Abstract][Full Text] [Related]
15. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
16. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
Gautam N; Kaur M; Kaur S
J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
[TBL] [Abstract][Full Text] [Related]
17. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
[TBL] [Abstract][Full Text] [Related]
18. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.
Jones BA; Varambally S; Arend RC
Mol Cancer Ther; 2018 Mar; 17(3):591-602. PubMed ID: 29726819
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
20. EZH2: a novel target for cancer treatment.
Duan R; Du W; Guo W
J Hematol Oncol; 2020 Jul; 13(1):104. PubMed ID: 32723346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]